Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Clinical trials of systemic therapies for atopic dermatitis (AD) often exclude patients based on age and comorbidities. We conducted a scoping review of observational studies and survey of International Eczema Council (IEC) members on the treatment of AD in patients with liver disease, renal disease, viral hepatitis, HIV, or history of malignancy. We searched MEDLINE via Ovid, Embase via Ovid, and Web of Science from inception to September 14, 2020. We mapped the available evidence on the use of cyclosporine, methotrexate, azathioprine, mycophenolate, systemic corticosteroids, and dupilumab for AD in older adults (≥65 years) and adults with the previously mentioned comorbidities. We surveyed IEC members on their preferred systemic medications for each patient population. We identified 25 studies on the use of systemic medications in special populations of adults with AD. Although IEC members preferred dupilumab as the first-line systemic agent across all special populations, many could not identify viable third-line systemic therapy options for some populations. Data on systemic therapy for AD for older adults and adults with comorbidities are limited. Although IEC members' access to systemic therapies differs geographically, expert opinion suggests that dupilumab is preferred for those patients. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Contact Dermatitis Society.

Citation

Aaron M Drucker, Megan Lam, Carsten Flohr, Jacob P Thyssen, Kenji Kabashima, Robert Bissonnette, Ncoza C Dlova, Valeria Aoki, Max Chen, Joshua Yu, Jie Wei Zhu, Robert Micieli, Audrey Nosbaum. Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey. Dermatitis : contact, atopic, occupational, drug. 2022 May-Jun 01;33(3):200-206

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 35170524

View Full Text